Eidos Therapeutics Inc (NASDAQ:EIDX) – Stock analysts at Svb Leerink cut their Q2 2019 earnings estimates for Eidos Therapeutics in a research note issued to investors on Tuesday, May 21st. Svb Leerink analyst M. Foroohar now forecasts that the company will post earnings of ($0.34) per share for the quarter, down from their prior forecast of ($0.31). Svb Leerink also issued estimates for Eidos Therapeutics’ Q3 2019 earnings at ($0.42) EPS, Q4 2019 earnings at ($0.52) EPS, FY2019 earnings at ($1.61) EPS and FY2020 earnings at ($2.45) EPS.

Other analysts have also recently issued reports about the stock. BTIG Research assumed coverage on shares of Eidos Therapeutics in a research note on Wednesday, April 17th. They set a “buy” rating and a $38.00 price objective for the company. BMO Capital Markets boosted their price objective on shares of Eidos Therapeutics from $28.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. Zacks Investment Research cut shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Finally, JPMorgan Chase & Co. raised shares of Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, February 27th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $30.29.

Shares of NASDAQ EIDX opened at $27.26 on Friday. Eidos Therapeutics has a 52-week low of $8.89 and a 52-week high of $29.74. The firm has a market cap of $1.01 billion and a PE ratio of -14.66. The company has a debt-to-equity ratio of 0.01, a current ratio of 19.04 and a quick ratio of 19.04.

Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings data on Monday, April 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.01).

In related news, insider Jonathan C. Fox sold 5,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $25.46, for a total transaction of $127,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christine Siu sold 11,913 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $19.66, for a total transaction of $234,209.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,913 shares of company stock valued at $732,760.

A number of institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new stake in shares of Eidos Therapeutics during the 3rd quarter worth approximately $137,000. BlackRock Inc. lifted its stake in shares of Eidos Therapeutics by 385.1% during the 3rd quarter. BlackRock Inc. now owns 727,698 shares of the company’s stock worth $7,264,000 after acquiring an additional 577,698 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Eidos Therapeutics by 297.3% during the 3rd quarter. Vanguard Group Inc. now owns 198,673 shares of the company’s stock worth $1,983,000 after acquiring an additional 148,673 shares during the last quarter. Vanguard Group Inc lifted its stake in shares of Eidos Therapeutics by 297.3% during the 3rd quarter. Vanguard Group Inc now owns 198,673 shares of the company’s stock worth $1,983,000 after acquiring an additional 148,673 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Eidos Therapeutics during the 4th quarter worth approximately $104,000. 31.63% of the stock is owned by hedge funds and other institutional investors.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Recommended Story: Rule of 72

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.